NASDAQ · STOK

Stoke Therapeutics, Inc.

Healthcare · Biotechnology

$28.65▼ 0.97% ($0.28)today

As of 3:15 PM ET

52-week

$20.32$40.22

Market cap

$1.85B

P/E

No multiple

What the market price implies · Reverse DCF

To support a price of $28.65, this model requires revenue to grow by 66.47%/yr over the next 10 years, compounded annually.

Historical revenue grew by 145.89%/yr over the past 3 years. The required annual growth rate is 79.42 percentage points lower.

Selected forecast · Base scenario

19.61%/yr · actual 10-year annualized revenue growth

Year 1 growth: 40%

Market-implied · Base operating assumptions + edited margins

66.47%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$28.65

Estimated value / share

$5.06

Base scenario

This estimate is 82.32% below the price used.

USD · TTM ending 2026-06-30

Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 40% · Ending margin 0% · Discount rate 11.77%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 7:15 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 18, 2026, 7:15 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Momentum disconnected from fundamentalsModerate confidence

1Y Price: 21.88%Revenue (TTM): -86.2%FCF (TTM): -395.49%P/S: 82nd pct

What changed

The stock rose 21.88% over the last year. Revenue declined 86.2% over the trailing twelve months. Operating margin moved from 20.15% to -809.69%. Free cash flow declined 395.49% over the trailing twelve months.

What the market seems to be pricing

The stock is rising despite deteriorating fundamentals and now sits at the 82nd percentile of its historical P/S range. This is a momentum-driven move — the market may be front-running a recovery that has not yet appeared in reported numbers.

What would invalidate this read

Operating margin (currently -809.69%) would need to stabilize or improve to justify the move. Revenue is declining 86.2% — a trend reversal in the next report would be the key signal to watch. This read is wrong if the next period shows operating metrics turning the corner. At that point the price would be anticipating real improvement rather than running ahead of it.

Performance

Return analysis

Company profile

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies.

CEOIan F. Smith

SectorHealthcare

IndustryBiotechnology

Employees170

IPO dateJun 19, 2019

https://www.stoketherapeutics.com

Market multiples

Forward P/E—

EV/EBITDA-351.59

Enterprise value$1.8B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-32.51%

Gross margin (FY2025)100%0.0ppvs FY2024

Operating margin (FY2025)-11.16%▲266.1ppvs FY2024

ROE-61.1%▼58.7ppvs FY2025

Analyst consensus

RatingBuy

Target price$51.00▲78.01%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est -$0.88 · Revenue est $8.21M

View